文献速递牙周病

玻连蛋白衍生肽通过调节骨重塑及RANKL和IL-17A表达预防并恢复牙槽骨丢失

A vitronectin-derived peptide prevents and restores alveolar bone loss by modulating bone re-modelling and expression of RANKL and IL-17A.
PubMed 文献 · J Clin Periodontol · 2022-06-16

本研究在大鼠和小鼠结扎诱导牙周炎模型中,局部给予玻连蛋白衍生肽VnP-16,并通过体外实验探讨机制。结果显示VnP-16促进人牙周膜细胞成骨分化、抑制炎症介质,并减少RANKL和IL-17A产生。局部给药显著预防并逆转牙槽骨丢失,提示其可能作为牙周炎治疗药物。

要点

  • VnP-16促进人牙周膜细胞成骨分化并抑制牙龈成纤维细胞炎症介质产生。
  • VnP-16减少表达RANKL的CD4+和CD8+ T细胞数量并抑制RANKL和IL-17A产生。
  • 大鼠和小鼠局部给予VnP-16显著预防并逆转结扎诱导的牙槽骨丢失。

核心结论

  • VnP-16通过调节骨重塑及免疫炎症反应,可能作为预防和治疗牙周炎的有效治疗药物。

研究设计与样本

  • 体外研究:评估VnP-16对人牙周膜细胞成骨分化、牙龈成纤维细胞脂多糖诱导炎症反应及T淋巴细胞免疫反应的影响。

主要发现

  • VnP-16促进人牙周膜细胞成骨分化,并抑制牙龈成纤维细胞中脂多糖诱导的炎症介质产生。
  • VnP-16减少脂多糖刺激的CD4+和CD8+ T细胞中表达RANKL的细胞数量,并抑制RANKL和IL-17A产生。
  • 在大鼠和小鼠中,局部给予VnP-16显著预防并逆转结扎诱导的牙槽骨丢失。
  • VnP-16在体内增强成骨细胞生成,同时抑制破骨细胞生成并抑制RANKL和IL-17A表达。

关键数值与推荐

  • 大鼠结扎双侧下颌第一磨牙14天诱导牙周炎,每组n=10,VnP-16(100 μg/10 μl)经龈沟内注射局部给药。
  • 小鼠结扎7天诱导牙周炎,每组n=10,VnP-16(50 μg/5 μl)经牙龈内注射直接给药。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This study investigated whether a vitronectin-derived peptide (VnP-16) prevents and/or reverses alveolar bone resorption induced by ligature-induced periodontitis in rodents and identified the underlying mechanism. MATERIALS AND METHODS: We evaluated the effects of VnP-16 on osteogenic differentiation in human periodontal ligament cells (hPDLCs), lipopolysaccharide-induced inflammatory responses in gingival fibroblasts, and immune response in T lymphocytes. Ligature-induced periodontitis was induced by ligating the bilateral mandibular first molars for 14 days in rats and for 7 days in mice (n = 10/group). VnP-16 (100 μg/10 μl) was applied topically into the gingival sulcus of rats via intra-sulcular injection, whereas the peptide (50 μg/5 μl) was administered directly into the gingiva of mice via intra-gingival injection. To evaluate the preventive and therapeutic effects of VnP-16, micro-computed tomography analysis and histological staining were then performed. RESULTS: VnP-16 promoted osteogenic differentiation of periodontal ligament cells and inhibited the production of lipopolysaccharide-induced inflammatory mediators in gingival fibroblasts. Concomitantly, VnP-16 modulated the host immune response by reducing the number of receptor activator of NF-κB ligand (RANKL)-expressing lipopolysaccharide-stimulated CD4+ and CD8+ T cells, and by suppressing RANKL and interleukin (IL)-17A production. Furthermore, local administration of VnP-16 in rats and mice significantly prevented and reversed alveolar bone loss induced by ligature-induced periodontitis. VnP-16 enhanced osteoblastogenesis and simultaneously inhibited osteoclastogenesis and suppressed RANKL and IL-17A expression in vivo. CONCLUSIONS: Our findings suggest that VnP-16 acts as a potent therapeutic agent for preventing and treating periodontitis by regulating bone re-modelling and immune and inflammatory responses.

来源:J Clin Periodontol,查看原文。版权归原作者所有。

引用

  1. Lee J, Min HK, Park CY, et al. A vitronectin-derived peptide prevents and restores alveolar bone loss by modulating bone re-modelling and expression of RANKL and IL-17A. J Clin Periodontol. 2022. PMID: 35634689. doi:10.1111/jcpe.13671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。